CrescNet gGmbH Leipzig.
Dtsch Arztebl Int. 2011 Feb;108(8):123-8. doi: 10.3238/arztebl.2011.0123. Epub 2011 Feb 25.
Growth hormone replacement therapy is more effective the earlier it is begun. This article adresses the question whether children with growth hormone deficiency (GHD) were able to begin treatment earlier through the use of the CrescNet system in the Department of Pediatrics at the Leipzig University Hospital. CrescNet is a network of pediatricians and endocrinological treatment centers, established in Leipzig in 1998, whose aim is to improve the early detection of growth disorders.
Pediatricians participating in CrescNet provided anonymized data on their patients' height and weight to the CrescNet database. Each participating pediatrician received a quarterly screening report with recommendations for the work-up of children with abnormal growth. Some patients with GHD who were treated in the Leipzig treatment center were referred in response to these recommendations, while others came spontaneously from the practices of pediatricians participating or not participating in CrescNet. We determined the age at the onset of treatment for the 139 patients treated for GHD in the University Children's Hospital Leipzig from 1999 to 2005 and compared the findings with data from other treatment centers in Germany.
Patients from CrescNet practices began treatment at a younger age than those from non-CrescNet practices (8.77 ± 3.40 versus 9.50 ± 3.78 years, p = 0.26). Patients from CrescNet practices whose GHD was detected by screening began treatment earlier than those for whom no data had been sent (7.67 ± 3.21 versus 9.28 ± 3.39 years, p = 0.031). In the center in Leipzig, but not in other German GHD treatment centers, the age at onset of treatment dropped significantly over the period of the study and then remained steady till 2009 in the range of 7.61 ± 3.0 years.
These descriptive results imply that the linking of pediatricians' practices with the CrescNet system resulted in earlier treatment of children with GHD.
生长激素替代疗法越早开始效果越好。本文探讨了通过莱比锡大学医院儿科的 CrescNet 系统，生长激素缺乏症（GHD）患儿是否能够更早开始治疗的问题。CrescNet 是一个由儿科医生和内分泌治疗中心组成的网络，于 1998 年在莱比锡成立，旨在提高生长障碍的早期发现。
参与 CrescNet 的儿科医生将其患者的身高和体重的匿名数据提供给 CrescNet 数据库。每位参与的儿科医生都会收到一份季度筛查报告，其中包含对生长异常儿童进行检查的建议。根据这些建议，一些在莱比锡治疗中心治疗的 GHD 患者被转诊，而另一些则来自参与或不参与 CrescNet 的儿科医生的实践。我们确定了 1999 年至 2005 年在莱比锡大学儿童医院治疗的 139 例 GHD 患者的治疗开始年龄，并将结果与德国其他治疗中心的数据进行了比较。
来自 CrescNet 实践的患者开始治疗的年龄比来自非 CrescNet 实践的患者小（8.77 ± 3.40 与 9.50 ± 3.78 岁，p = 0.26）。通过筛查发现 GHD 的 CrescNet 实践患者比未发送数据的患者更早开始治疗（7.67 ± 3.21 与 9.28 ± 3.39 岁，p = 0.031）。在莱比锡中心，但不是在德国其他 GHD 治疗中心，治疗开始的年龄在研究期间显著下降，然后在 2009 年之前稳定在 7.61 ± 3.0 岁的范围内。
这些描述性结果表明，将儿科医生的实践与 CrescNet 系统联系起来，可以更早地治疗 GHD 患儿。
